title: Initial therapy for type 2 diabetes. Examination of a combination approach.
authors.affiliation: Regional Medical Associates, Draffenville, KY, USA.
authors.forename: Kayla
authors.initials: K
authors.lastname: Henson
authors.forename: Rita
authors.initials: R
authors.lastname: Hight
authors.forename: Donna
authors.initials: D
authors.lastname: Welborn
authors.forename: Sheryl
authors.initials: S
authors.lastname: Wyatt
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D055317:Evidence-Based Practice; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D009722:Nurse Practitioners / Q000458:organization & administration; D017410:Practice Guidelines as Topic; D011320:Primary Health Care / Q000458:organization & administration; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin; D011719:Pyrazines; D000068900:Sitagliptin Phosphate; D014230:Triazoles